Multiple System Atrophy Pipeline Drugs Review H1 2017 (1)

1
Multiple System Atrophy - Pipeline Review H1
2017

• Published  June 2017 Single User
  US 2000
• No. of Pages 33 Corporate User US
  6000

www.ReportsandReports.com
Website
2
Multiple System Atrophy Pipeline Market Reviews
in H1 2017 Report

• Multiple System Atrophy Pipeline Drugs and
  Therapeutics Review H1 2017 provide an overview
  of the Multiple System Atrophy (Central Nervous
  System) pipeline landscape. Pharmaceutical and
  Healthcare latest pipeline guide Multiple System
  Atrophy - Pipeline Review, H1 2017, provides
  comprehensive information on the therapeutics
  under development for Multiple System Atrophy
  (Central Nervous System), complete with analysis
  by stage of development, drug target, mechanism
  of action (MoA), route of administration (RoA)
  and molecule type. The guide covers the
  descriptive pharmacological action of the
  therapeutics, its complete research and
  development history and latest news and press
  releases.
• Multiple System Atrophy (Central Nervous System)
  pipeline therapeutics guide also reviews of key
  players involved in therapeutic development for
  Multiple System Atrophy (MSA or Shy-Drager
  Syndrome or Multi-System Degeneration) and
  features dormant and discontinued projects. The
  guide covers therapeutics under Development by
  Companies /Universities /Institutes, the
  molecules developed by Companies in Phase I,
  IND/CTA Filed, Preclinical and Discovery stages
  are 3, 1, 3 and 1 respectively.

Access Complete Report at http//www.reportsnr
eports.com/reports/1057929-multiple-system-atrophy
-pipeline-review-h1-2017.html.
3
Multiple System Atrophy Pipeline Market Reviews
in H1 2017 Report

• Multiple System Atrophy - Companies Involved in
  Therapeutics Development Discussed AFFiRiS AG,
  Corestem Inc, Neuropore Therapies Inc, Prana
  Biotechnology Ltd.
• Multiple System Atrophy Drug Profiles Discussed
  Anle-138b, CS-10BR05, ENT-01, NPT-20011, PBT-434,
  PD-01, PD-03, Small Molecules for
  Neurodegenerative Disease.
• Multiple System Atrophy (Central Nervous System)
  pipeline guide helps in identifying and tracking
  emerging players in the market and their
  portfolios, enhances decision making capabilities
  and helps to create effective counter strategies
  to gain competitive advantage. The guide is built
  using data and information sourced proprietary
  databases, company/university websites, clinical
  trial registries, conferences, SEC filings,
  investor presentations and featured press
  releases from company/university sites and
  industry-specific third party sources.
  Additionally, various dynamic tracking processes
  ensure that the most recent developments are
  captured on a real time basis.

Get Discount at http//www.reportsnreports.com/con
tacts/discount.aspx?name1057929.
4
Multiple System Atrophy Pipeline Market Reviews
in H1 2017 Report

• Scope
• The pipeline guide provides a snapshot of the
  global therapeutic landscape of Multiple System
  Atrophy (Central Nervous System).The pipeline
  guide reviews pipeline therapeutics for Multiple
  System Atrophy (Central Nervous System) by
  companies and universities/research institutes
  based on information derived from company and
  industry-specific sources.The pipeline guide
  covers pipeline products based on several stages
  of development ranging from pre-registration till
  discovery and undisclosed stages.The pipeline
  guide features descriptive drug profiles for the
  pipeline products which comprise, product
  description, descriptive licensing and
  collaboration details, RD brief, MoA other
  developmental activities.The pipeline guide
  reviews key companies involved in Multiple System
  Atrophy (Central Nervous System) therapeutics and
  enlists all their major and minor projects.The
  pipeline guide evaluates Multiple System Atrophy
  (Central Nervous System) therapeutics based on
  mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.The
  pipeline guide encapsulates all the dormant and
  discontinued pipeline projects.The pipeline guide
  reviews latest news related to pipeline
  therapeutics for Multiple System Atrophy (Central
  Nervous System).
• Buy Complete Report at http//www.reportsnreports.
  com/purchase.aspx?name1057929

5
Multiple System Atrophy Pipeline Market Reviews
in H1 2017 Report
List of Tables 1.Number of Products under
Development for Multiple System Atrophy (MSA or
Shy-Drager Syndrome or Multi-System
Degeneration), H1 2017 2.Number of Products under
Development by Companies, H1 2017 3.Products
under Development by Companies, H1 2017 4.Number
of Products by Stage and Target, H1 2017 5.Number
of Products by Stage and Mechanism of Action, H1
2017 6.Number of Products by Stage and Route of
Administration, H1 2017 7.Number of Products by
Stage and Molecule Type, H1 2017 8.Multiple
System Atrophy (MSA or Shy-Drager Syndrome or
Multi-System Degeneration) - Pipeline by AFFiRiS
AG, H1 2017 9.Multiple System Atrophy (MSA or
Shy-Drager Syndrome or Multi-System Degeneration)
- Pipeline by Corestem Inc, H1 2017 10.Multiple
System Atrophy (MSA or Shy-Drager Syndrome or
Multi-System Degeneration) - Pipeline by
Neuropore Therapies Inc, H1 2017 11.Multiple
System Atrophy (MSA or Shy-Drager Syndrome or
Multi-System Degeneration) - Pipeline by Prana
Biotechnology Ltd, H1 2017 12.Multiple System
Atrophy (MSA or Shy-Drager Syndrome or
Multi-System Degeneration) - Discontinued
Products, H1 2017
5
6
About Us

• ReportsnReports.com is your single source for all
  market research needs. Our database includes
  500,000 market research reports from over 95
  leading global publishers in-depth market
  research studies of over 5000 micro markets.
• We provide 24/7 online and offline support to our
  customers.
• Tel Phone No 1-888-391-5441 E-mail
  sales_at_reportsnreports.com

www.ReportsandReports.com
Website
www.ReportsandReports.com
Website